When does Farxiga’s (dapagliflozin) Australia patent coverage end?
I can’t answer this from the information provided. Patent end dates depend on the specific Australian patent number(s) and the jurisdiction’s status (granted, under litigation, term adjustments, and any pediatric/extension rules). Without the exact patent(s) tied to Farxiga in Australia (and whether you mean the first patent expiring or the last relevant one), any date would be guesswork.
Which exact patent(s) control generic entry in Australia?
Generic entry in Australia is usually driven by whether there is still an enforceable “active” patent covering the product (the drug substance, composition, or specific medical use) rather than a single headline patent. People typically need to know:
- the Australian patent number(s) covering Farxiga in Australia
- whether any are still in force (or partially invalidated)
- whether there are regulatory-driven exclusivities or court stays tied to that patent
How to find the correct expiry date quickly
If you share either the Australian patent number(s) or a link to the IP record you’re using, I can translate that into an expiry/term explanation in plain language. Otherwise, the fastest way to get the right answer is to look up the relevant patent(s) in Australia’s patent database and check the status and term end date(s).
If you meant “patent + exclusivity,” what else could extend availability?
Even if a primary patent expires, other patents (method of use, formulations, combinations) can delay market entry. Also, Australian market exclusivity mechanics can depend on the specific regulatory pathway the generic uses. The only way to be precise is to identify the specific patents listed against the product in Australia.
If you paste the Australian patent number(s) for Farxiga that you’re asking about (or tell me which one you mean), I’ll give you the exact “loss”/expiry date for that patent in Australia.